心房中膈缺损症市场（按产品类型、治疗类型、年龄层、最终用户和缺损类型）—2025-2030 年全球预测

心房中膈缺损症市场预计到 2024 年将达到 39.9 亿美元，到 2025 年将达到 42.7 亿美元，到 2030 年将达到 60.9 亿美元，复合年增长率为 7.27%。

主要市场统计数据
基准年2024年	39.9亿美元
预计2025年	42.7亿美元
预计2030年	60.9亿美元
复合年增长率（%）	7.27%

深入研究临床、技术和病患动态，为了解心房中膈缺损症市场奠定基础

心房中膈缺损症)是临床实践中最常见的先天性心臟疾病之一，涉及动态、解剖学和患者个体差异等复杂因素的相互作用。患有此缺陷的患者通常会出现一系列临床表现，从无症状到运动耐受性降低、心律不整和右心室超负荷。病人历程如此多样化，凸显了精准诊断途径和个人化治疗性介入介入的必要性。

透过创新、政策演进和以病人为中心的治疗策略，重塑心房中膈缺损症生态系统

心房中膈缺损症市场正在经历一场变革性的转变，这得益于器械工程的突破、报销模式的转变以及对以患者为中心的护理模式的重视。器械创新者正在突破微型化和生物相容性的极限，并融入先进的聚合物复合材料和形状记忆合金，使其能够无缝贴合房间隔的解剖结构。同时，从远端血流动力学监测到人工智慧影像分析等数位健康工具的整合，使临床医生能够个人化手术计划并优化追踪通讯协定。

评估 2025 年美国关税对介入性心臟病学设备供应链、成本结构和策略市场定位的影响

美国将于2025年实施新的关税，为心房中膈缺损症器械的供应链计算带来了关键变数。对进口零件和成品征收分级关税，导致製造商从原材料采购到最终器械组装的各个环节成本上升。为此，领先的医疗设备製造商正在调整筹资策略，并与本地伙伴关係合作，以减轻关税波动的影响，并确保零件的持续供应。

揭示自闭症领域的产品类型、治疗方式、年龄层、最终用户和缺陷变化的关键细分洞察

详细的細項分析揭示了心房中膈缺损症市场的多面性。按产品类型划分，该市场包括心肺体外迴圈装置、封堵装置和诊断设备。在封堵解决方案中，阻塞设备与外科补片并列。外科补片又进一步分为球囊扩张型和自扩张式，而补片则可由生物或合成材料製成。诊断功能涵盖心导管装置、先进的影像系统和专用的超音波心动图平台。这种层级结构凸显了在不同技术丛集中进行有针对性创新的重要性。

了解美洲、欧洲、中东和非洲以及亚太地区心房中膈缺损症市场的区域差异

心房中膈缺损症)治疗的区域动态呈现出显着的异质性。在美洲，完善的报销途径、早期采用机构以及强大的临床试验网络，支援尖端设备技术的快速普及。这种环境促进了医疗中心与产业创新者之间的合作伙伴关係，从而加速了设备的迭代改进和真实世界证据的产生。

介绍推动心房中膈缺损症管理技术进步和协作方法的市场领导和新兴创新者

心房中膈缺损症解决方案的竞争格局呈现两极化：成熟医疗设备公司和敏捷的新参与企业。现有企业利用其深厚的临床关係和广泛的分销网络，不断改进器械设计和输送系统。这些升级通常着重于改善器材贴合度、减小外形尺寸，并在置入过程中整合即时影像回馈。

可行的策略建议，以增强市场定位、推动创新并改善心房中膈缺损症治疗的患者预后

产业领导者应优先投资微创设备平台，以降低手术复杂性并改善患者復原轨迹。将研发资源导向生物相容性材料和下一代输送系统，有助于企业实现产品差异化，并满足尚未满足的临床需求。此外，与契约製造製造商和物流专家建立策略伙伴关係关係，可以增强供应链在不断变化的贸易政策中的韧性。

整合主要相关人员调查、二手文献综述和严格的资料检验过程的综合调查方法

本分析基于严谨的研究框架，整合了主要研究方法和次要研究方法。主要研究包括对介入性心臟病专家、心胸外科医生、采购专业人员、付款人和医疗保健管理人员进行结构化访谈和调查，以了解设备性能、临床工作流程和经济因素的真实观点。此外，由临床专家组成的共识小组对这些见解进行了补充，以检验关键发现并解读新兴趋势。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 新型生物分解性降解封堵材料减少併发症，提高经导管封堵术的采用率
• 增加对人工智慧心臟超音波图的投资，以实现早期发现和个人化自闭症治疗计划
• 越来越多的临床试验评估经皮装置对患有复杂性心房中膈缺损症的成年患者的作用
• 设备製造商和心臟中心在开发微创 ASD 修復技术方面的合作正在增多
• 新兴国家结构性心臟介入的报销政策扩大将推动市场成长

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第八章心房中膈缺损症市场（依产品类型）

• 心肺体外迴圈机
• 封闭装置
  • 阻塞设备
    • 球囊扩张型封堵器
    • 自膨胀式闭孔器
  • 手术补片
    • 生物补丁
    • 合成补片
• 诊断设备
  • 心导管插入装置
  • 心臟影像系统
  • 心臟超音波图系统

第九章心房中膈缺损症市场（依治疗类型）

• 介入治疗
• 非介入治疗

第十章。心房中膈缺损症市场（依年龄层）

• 成人
• 小儿科
  • 青春期
  • 婴儿
  • 新生

第 11 章。心房中膈缺损症市场（按最终用户）

• 门诊手术中心
• 心臟中心
• 医院

第 12 章心房中膈缺损症市场（按缺损类型）

• 冠状窦
• 原发孔
• 第二口
• 静脉窦

13. 美国心房中膈缺损症市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

14. 欧洲、中东和非洲心房中膈缺损症市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

15. 亚太地区心房中膈缺损症市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十六章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • WL Gore & Associates, Inc.
  • Asklepion Pharmaceuticals, LLC
  • atHeart Medical AG
  • B. Braun Medical Inc.
  • Boston Scientific Corporation
  • Carag AG
  • Edwards Lifesciences
  • GE HealthCare Technologies, Inc.
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd
  • Lifetech Scientific
  • Occlutech GmbH
  • Visionary Medtech Solutions
  • Weigao Meidcal international Co., Ltd

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

The Atrial Septal Defect Market was valued at USD 3.99 billion in 2024 and is projected to grow to USD 4.27 billion in 2025, with a CAGR of 7.27%, reaching USD 6.09 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.99 billion
Estimated Year [2025]	USD 4.27 billion
Forecast Year [2030]	USD 6.09 billion
CAGR (%)	7.27%

Laying the Foundation for Atrial Septal Defect Market Understanding Through Deep Dive into Clinical, Technological, and Patient Dynamics

Atrial septal defect represents one of the most prevalent congenital heart anomalies encountered in clinical practice, presenting an intricate interplay of hemodynamic, anatomical, and patient-specific factors. Patients with this defect often experience a spectrum of clinical manifestations, ranging from asymptomatic presentations to compromised exercise tolerance, arrhythmias, and right ventricular overload. These diverse patient journeys underscore the critical need for precise diagnostic pathways and tailored therapeutic interventions.

Advancements in diagnostic modalities, including enhancements in intracardiac echocardiography, sophisticated imaging software, and catheterization techniques, have facilitated earlier and more accurate detection of septal defects. At the same time, novel occlusion devices and bioengineered patches are redefining the interventional landscape, offering less invasive options and reduced recovery times. This technological momentum is paralleled by evolving clinical guidelines, which increasingly emphasize patient stratification based on defect size, anatomical location, and comorbid conditions.

Beyond technological and clinical progress, the economic and regulatory backdrop shapes the innovation trajectory. Healthcare payers and regulatory bodies are driving value-based reimbursement frameworks that reward demonstrable improvements in patient outcomes. Consequently, manufacturers and healthcare providers must align research and development initiatives with real-world evidence generation, forging a nexus between clinical efficacy and cost efficiency. This introductory overview sets the stage for a deeper exploration of transformative shifts, policy impacts, and actionable strategies within the atrial septal defect market.

Transformative Shifts Reshaping the Atrial Septal Defect Ecosystem Driven by Innovation, Policy Evolution, and Patient-Centric Care Strategies

The atrial septal defect market is undergoing transformative shifts propelled by breakthroughs in device engineering, shifts in reimbursement paradigms, and an intensified focus on patient-centered care models. Device innovators are pushing the boundaries of miniaturization and biocompatibility, incorporating advanced polymer composites and shape-memory alloys that conform seamlessly to septal anatomy. Simultaneously, the integration of digital health tools-ranging from remote hemodynamic monitoring to AI-enhanced imaging analyses-is enabling clinicians to personalize procedural plans and optimize follow-up protocols.

Concurrently, regulatory authorities in key markets are adopting more streamlined approval pathways for next-generation devices, contingent upon robust post-market surveillance and real-world data collection. These adjustments aim to balance rapid patient access with long-term safety validation. Payer ecosystems are realigning their criteria to support interventions that demonstrate quantifiable reductions in hospital readmissions and improved quality-adjusted life years. Value-based contracting models are incentivizing providers to prioritize durable, cost-effective solutions that deliver sustained clinical benefits.

Moreover, patient advocacy groups and multidisciplinary care teams are elevating the voice of patients in treatment planning, fostering shared decision-making frameworks. This patient empowerment trend underscores the importance of educational initiatives and transparent risk-benefit communication. Together, these transformative forces are reshaping the atrial septal defect landscape from a siloed, procedure-focused environment into an interconnected ecosystem centered on patient outcomes, evidence generation, and integrated care delivery.

Assessing the Impact of United States Tariffs in 2025 on Device Supply Chains, Cost Structures, and Strategic Market Positioning for Cardiac Interventions

The introduction of new tariff structures by the United States in 2025 has introduced a pivotal variable into the supply chain calculus for atrial septal defect devices. By imposing incremental duties on imported components and finished products, manufacturers are encountering elevated costs that reverberate from raw-material procurement through final device assembly. In response, leading device producers are reassessing their sourcing strategies, forging partnerships with regional suppliers to mitigate exposure to duty fluctuations and ensure continuity of component availability.

These strategic shifts are accompanied by renegotiations of commercial agreements with contract manufacturers and logistics providers, aiming to absorb or distribute tariff-related cost pressures. Some stakeholders have accelerated investments in domestic manufacturing capabilities, seeking to qualify for tariff exemptions associated with localized production. While these initiatives may require significant upfront capital, they promise resilience against future trade policy volatility and may unlock incentives tied to domestic job creation.

On the clinical front, hospitals and surgical centers are recalibrating purchasing committees and budget allocations to accommodate the revised cost profiles. Procurement teams are engaging in more rigorous total cost of ownership analyses, balancing device efficacy against lifecycle maintenance and potential tariff escalations. This collective realignment underscores a broader trend: the convergence of trade policy considerations with strategic supply chain management and fiscal stewardship.

Unveiling Key Segmentation Insights into Product Types, Treatment Modalities, Age Demographics, End Users, and Defect Variants in the ASD Arena

In-depth segmentation analysis reveals the multifaceted nature of the atrial septal defect market. When examined through the lens of product type, the landscape comprises cardiopulmonary bypass devices, closure devices, and diagnostic equipment. Within closure solutions, occluder devices stand alongside surgical patches; the former category breaks down further into balloon-expandable and self-expanding variants, while patches may be derived from biologic or synthetic materials. Diagnostic capabilities span cardiac catheterization equipment, advanced imaging systems, and dedicated echocardiography platforms. This layered hierarchy underscores the importance of targeted innovation across distinct technology clusters.

Treatment modalities further refine the market, splitting into interventional and non-interventional approaches. Interventional therapies harness catheter-based technologies and device implants to achieve defect closure with minimal invasiveness, whereas non-interventional options focus on pharmacologic management and monitoring to address hemodynamic burden. Age stratification also plays a defining role: adult and pediatric cohorts exhibit divergent clinical trajectories, with the latter subdivided into neonatal, infant, and adolescent categories, each with unique anatomical and physiological considerations.

End users span ambulatory surgical centers, dedicated cardiac centers, and hospital settings, reflecting varying infrastructure requirements and patient acuity levels. Defect type segmentation highlights coronary sinus, ostium primum, ostium secundum, and sinus venosus anomalies, each necessitating specialized therapeutic frameworks. Understanding these intersecting segmentation dimensions is critical for stakeholders seeking to tailor product development, direct clinical education, and refine market entry strategies.

Decoding Regional Variations in Atrial Septal Defect Markets Across Americas, Europe, Middle East & Africa, and Asia-Pacific Landscapes

Regional dynamics in the atrial septal defect space exhibit notable heterogeneity. In the Americas, well-established reimbursement pathways and early adopter institutions support rapid assimilation of cutting-edge device technologies, coupled with robust clinical trial networks. This environment fosters collaborative partnerships between medical centers and industry innovators, accelerating iterative device enhancements and real-world evidence generation.

Across Europe, the Middle East, and Africa, regulatory landscapes vary widely, from the European Union's centralized approval systems to region-specific health authority processes. This diversity presents both challenges and opportunities; agile manufacturers can navigate these processes by aligning on harmonized clinical dossiers while engaging with regional regulatory experts. Moreover, emerging markets within this zone show increasing adoption of minimally invasive therapies as healthcare infrastructure expands.

In the Asia-Pacific realm, rapid healthcare investment is driving capacity growth in tertiary care facilities, especially in urban centers. Yet cost-containment pressures remain prominent, prompting local manufacturers and multinational corporations to pursue tiered pricing models and technology transfers. Digital health initiatives, including teleconsultation and remote monitoring platforms, are also gaining traction, offering pathways to bridge resource gaps and extend specialist expertise to broader patient populations. These diverse regional contours highlight the imperative for tailored market approaches that resonate with local clinical, economic, and regulatory contexts.

Profiling Market Leaders and Emerging Innovators Driving Technological Advances and Collaborative Approaches in Atrial Septal Defect Management

The competitive arena for atrial septal defect solutions is characterized by a blend of established medical device companies and agile newcomers. Incumbent firms have leveraged deep clinical relationships and expansive distribution networks to introduce iterative upgrades in device design and delivery systems. These upgrades often focus on enhancing device conformability, reducing profile size, and integrating real-time imaging feedback during implantation.

At the same time, emerging players are capturing attention through disruptive innovations such as bioresorbable occluders and next-generation polymer patches that promote tissue regeneration. Collaborative preclinical studies with academic institutions are underpinning these advances, providing critical safety and efficacy data. Additionally, there is a discernible shift toward digital integration, with companies embedding sensor technologies and connectivity features into their devices to support remote monitoring and patient engagement applications.

Strategic alliances, joint ventures, and selective acquisitions have become commonplace as organizations strive to fortify their product portfolios and accelerate entry into adjacent markets. This collaborative ecosystem is fostering cross-disciplinary R&D efforts that marry materials science, engineering prowess, and clinical insights. As a result, the market is witnessing a proliferation of modular solutions that offer scalability across clinical settings, from pediatric catheterization labs to high-throughput surgical suites.

Actionable Strategic Recommendations to Elevate Market Positioning, Foster Innovation, and Enhance Patient Outcomes in Atrial Septal Defect Care

Industry leaders should prioritize investment in minimally invasive device platforms that reduce procedural complexity and enhance patient recovery trajectories. By channeling R&D resources toward bioadaptive materials and next-generation delivery systems, organizations can differentiate their product offerings and address unmet clinical needs. Furthermore, forging strategic partnerships with contract manufacturers and logistics specialists will bolster supply chain resilience amid shifting trade policies.

Parallel to product innovation, developing comprehensive real-world evidence frameworks is essential. This requires collaboration with key opinion leaders, registry coordinators, and payers to capture longitudinal patient outcomes and cost metrics. Demonstrating sustained value through outcomes data will facilitate adoption in value-based reimbursement models and reinforce clinical trust.

Engaging patient advocacy groups and multidisciplinary care teams early in the development cycle can refine product design and ensure alignment with patient priorities. Finally, exploring geographic expansion opportunities in high-growth regions demands customized market access strategies that respect local regulatory nuances and affordability dynamics. Implementing these recommendations will position organizations to navigate market complexities, foster clinician partnerships, and ultimately deliver superior care for patients with atrial septal defects.

Comprehensive Research Methodology Integrating Primary Stakeholder Engagement, Secondary Literature Review, and Rigorous Data Validation Processes

This analysis is grounded in a rigorous research framework combining primary and secondary methodologies. Primary research involved structured interviews and surveys with interventional cardiologists, cardiothoracic surgeons, procurement specialists, payers, and healthcare administrators to capture real-world perspectives on device performance, clinical workflows, and economic considerations. These insights were complemented by consensus panels with clinical experts to validate key findings and interpret emerging trends.

Secondary research encompassed an exhaustive review of peer-reviewed journals, regulatory filings, conference proceedings, patent databases, and company disclosures to construct a robust evidence base. Publicly available healthcare datasets and procedural registries were interrogated to identify utilization patterns and geographic adoption curves. Data triangulation techniques were applied throughout to reconcile discrepancies between sources and enhance the credibility of conclusions.

Quality control processes included systematic cross-validation of quantitative data points and iterative reviews by an internal research governance committee. Expert validation workshops provided additional scrutiny, ensuring that assumptions, segmentation frameworks, and strategic recommendations reflect the current state of the atrial septal defect market and are poised to withstand future shifts.

The landscape of atrial septal defect management is defined by concurrent forces of innovation, policy evolution, and shifting patient expectations. Advancements in device engineering and diagnostic modalities continue to drive clinical adoption, while evolving reimbursement frameworks are incentivizing tangible improvements in long-term patient outcomes. Supply chain realignments, influenced by recent trade policy changes, underscore the importance of agility and domestic capability expansion to mitigate cost pressures.

Segmentation insights highlight the multifaceted nature of this market, from diverse product categories and treatment pathways to nuanced age and defect-type considerations. Regional analyses reveal distinct growth drivers and access barriers, necessitating tailored approaches in the Americas, Europe, Middle East & Africa, and Asia-Pacific contexts. Meanwhile, the interplay between established players and emerging innovators is catalyzing collaborative advances that align engineering breakthroughs with clinical evidence.

Collectively, these insights form an integrated perspective on market dynamics, strategic imperatives, and areas of opportunity. Organizations that embrace data-driven decision-making, cultivate stakeholder partnerships, and invest in patient-centric innovation are best positioned to thrive in this evolving ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Growth in transcatheter closure adoption driven by novel biodegradable occluders reducing complications
• 5.2. Rising investment in AI-enabled echocardiography for early detection and personalized ASD treatment planning
• 5.3. Increased clinical trials evaluating percutaneous device performance in adult patients with complex atrial septal defects
• 5.4. Surge in collaboration between device manufacturers and cardiology centers to develop minimally invasive ASD repair techniques
• 5.5. Expansion of reimbursement policies for structural heart interventions fueling market growth in emerging economies

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Atrial Septal Defect Market, by Product Type

• 8.1. Introduction
• 8.2. Cardiopulmonary Bypass Devices
• 8.3. Closure Devices
  • 8.3.1. Occluder Devices
    • 8.3.1.1. Balloon-Expandable Occluders
    • 8.3.1.2. Self-Expanding Occluders
  • 8.3.2. Surgical Patches
    • 8.3.2.1. Biologic Patches
    • 8.3.2.2. Synthetic Patches
• 8.4. Diagnostic Devices
  • 8.4.1. Cardiac Catheterization Equipment
  • 8.4.2. Cardiac Imaging Systems
  • 8.4.3. Echocardiography Systems

9. Atrial Septal Defect Market, by Treatment Type

• 9.1. Introduction
• 9.2. Interventional Treatment
• 9.3. Non-Interventional Treatment

10. Atrial Septal Defect Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Pediatric
  • 10.3.1. Adolescent
  • 10.3.2. Infant
  • 10.3.3. Neonatal

11. Atrial Septal Defect Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Cardiac Centers
• 11.4. Hospitals

12. Atrial Septal Defect Market, by Defect Type

• 12.1. Introduction
• 12.2. Coronary Sinus
• 12.3. Ostium Primum
• 12.4. Ostium Secundum
• 12.5. Sinus Venosus

13. Americas Atrial Septal Defect Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Atrial Septal Defect Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Atrial Septal Defect Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. W. L. Gore & Associates, Inc.
  • 16.3.3. Asklepion Pharmaceuticals, LLC
  • 16.3.4. atHeart Medical AG
  • 16.3.5. B. Braun Medical Inc.
  • 16.3.6. Boston Scientific Corporation
  • 16.3.7. Carag AG
  • 16.3.8. Edwards Lifesciences
  • 16.3.9. GE HealthCare Technologies, Inc.
  • 16.3.10. Koninklijke Philips N.V.
  • 16.3.11. Lepu Medical Technology (Beijing) Co., Ltd
  • 16.3.12. Lifetech Scientific
  • 16.3.13. Occlutech GmbH
  • 16.3.14. Visionary Medtech Solutions
  • 16.3.15. Weigao Meidcal international Co., Ltd

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

• FIGURE 1. ATRIAL SEPTAL DEFECT MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ATRIAL SEPTAL DEFECT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. ATRIAL SEPTAL DEFECT MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. ATRIAL SEPTAL DEFECT MARKET: RESEARCHAI
• FIGURE 26. ATRIAL SEPTAL DEFECT MARKET: RESEARCHSTATISTICS
• FIGURE 27. ATRIAL SEPTAL DEFECT MARKET: RESEARCHCONTACTS
• FIGURE 28. ATRIAL SEPTAL DEFECT MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. ATRIAL SEPTAL DEFECT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIOPULMONARY BYPASS DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIOPULMONARY BYPASS DEVICES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BALLOON-EXPANDABLE OCCLUDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BALLOON-EXPANDABLE OCCLUDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SELF-EXPANDING OCCLUDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SELF-EXPANDING OCCLUDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BIOLOGIC PATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BIOLOGIC PATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYNTHETIC PATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYNTHETIC PATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CATHETERIZATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CATHETERIZATION EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC IMAGING SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ECHOCARDIOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ECHOCARDIOGRAPHY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INTERVENTIONAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INTERVENTIONAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NON-INTERVENTIONAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NON-INTERVENTIONAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INFANT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NEONATAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CORONARY SINUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CORONARY SINUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM PRIMUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM PRIMUM, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM SECUNDUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM SECUNDUM, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SINUS VENOSUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SINUS VENOSUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 82. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 83. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 84. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 85. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 86. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 87. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 88. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 89. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 90. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 103. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 104. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 105. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 106. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 107. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 108. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 109. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 110. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 125. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 126. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 127. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 128. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 129. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 130. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 131. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 132. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 133. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 134. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 135. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 137. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 138. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 139. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 140. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 141. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 142. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 143. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 144. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 145. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 146. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 147. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 148. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 149. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 150. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 151. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 152. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 161. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 165. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 166. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 167. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 168. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 169. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 170. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 179. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 180. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 181. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 185. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 186. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 187. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 188. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 191. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 192. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 197. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 198. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 199. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 200. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 201. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 203. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 204. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 230. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 232. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 234. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 236. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 242. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 243. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 245. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 246. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 247. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 249. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 250. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 251. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 252. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 253. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 255. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 257. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 259. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 261. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 262. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 263. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 265. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 266. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 267. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 269. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 270. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 271. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 272. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 273. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 274. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 275. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 276. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 277. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 279. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 280. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 281. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 282. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 283. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 285. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 287. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 288. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 289. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 290. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 291. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 292. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 293. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 294. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 295. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 296. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 297. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 299. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 300. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 301. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 302. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 303. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 305. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 307. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 308. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 309. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 310. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 311. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 312. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 313. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 314. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-2030 (USD MILLION)
• TABLE 315. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
• TABLE 316. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
• TABLE 317. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
• TABLE 319. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 320. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 321. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 322. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 323. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 324. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 325. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2024 (USD MILLION)
• TABLE 326. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025-2030 (USD MILLION)
• TABLE 327. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 328. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 329. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2024 (USD MILLION)
• TABLE 330. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2025-2030 (USD MILLION)
• TABLE 331. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2024 (USD MILLION)
• TABLE 332. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2025-2030 (USD MILLION)
• TABLE 333. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2024 (USD MILLION)
• TABLE 334. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2025-20